HDAC inhibitor drugs approved

Last week the FDA approved Italfarmaco’s givinostat (ITF2357) for Duchenne muscular dystrophy. Givinostat is a novel histone deacetylase (HDAC) inhibitor and was approved for DMD patients six years or older.
 

Also last week, the FDA granted accelerated approval to ponatinib – with chemotherapy – for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Ponatinib (AP24534) is a potent pan-Bcr-Abl and multikinase inhibitor.
 

Focus biomolecules offers ponatinib for research applications, amongst many other kinase inhibitors. We can also supply givinostat – contact us. Browse our collection of other HDAC inhibitors.